Tata Steel share price declined 1.8 percent on Friday after reports of fire at its UK-based steel plant. The company shared the fire was contained but there was damage at the steel plant.
News in Focus
Featured, India Business, Analyst View, Stock Markets, ICICI Securities, India, Indo Count Industries, Textile Sector
ICICI Securities has retained its BUY call on Indo Count Industries, setting a revised 12-month target of Rs 418, versus a current market price of Rs 344.
Featured, India Business, Analyst View, Stock Markets, Engineering Sector, ICICI Direct, India, Siemens
ICICI Securities has maintained a HOLD rating on Siemens Ltd., with a 12-month target price of Rs 4,190, implying about 12% upside from the current market price of Rs 3,750.
ICICI Securities has reiterated a BUY recommendation on Kajaria Ceramics, setting a target price of Rs 1,300, implying about 17% upside from the current market price of Rs 1,114 over a 12-m
ICICI Securities has reiterated a Buy call on Lemon Tree Hotels Ltd., with a revised target price of Rs 142, implying 29% upside from the CMP of Rs 110 over a 12-month horizon.
Featured, India Business, Company Results, Analyst View, Greenpanel Industries, India, Prabhudas Lilladher
Prabhudas Lilladher has retained a BUY recommendation on Greenpanel Industries, with a target price of Rs 332 against a current market price of Rs 186, signaling substantial upside
Main Regional Stories
Motilal Oswal has reiterated a BUY call on NMDC and pegged a target price of Rs 106, implying about 15% upside from the current market price of Rs 92.
IDBI Capital has suggested BUY Call for Lemon Tree Hotels with Target Price at Rs 165 compared to current price ranging between Rs 110-115.
Axis Securities has upgraded Asian Paints to a BUY rating with a revised target price of Rs 3,130 per share, implying an upside potential of approximately 17% from the current market price of Rs 2,672.
Featured, India Business, Analyst View, Glenmark Pharmaceuticals, India, Motilal Oswal, Pharmaceutical Sector
Motilal Oswal has reiterated a BUY call on Glenmark Pharma, with a target price of Rs2,610 and an implied upside of 19% from the current market price of Rs2,201.
